PhRMApedia Press Room
PhRMApedia's Press Room will provide the most recent press releases. Search PhRMApedia for additional press releases. PhRMApedia is your new resource hub. You can search our entire database of media releases, reports, white papers, videos and more. Type your keywords in the search bar and explore PhRMA’s resources. Search results will appear by type, title and date.
WASHINGTON, D.C. (April 27, 2016) – Pharmaceutical Research and Manufacturers of America (PhRMA) Vice President Jay Taylor issued the following statement today:
“PhRMA members appreciate the continuing work of the Office of the U.S. Trade Representative (USTR), the Departments of State and Commerce, U.S. overseas missions and others to establish and ensure full compliance with strong rules protecting patents and other intellectual property rights abroad. Special 301 is an essential tool to bring high-level attention to intellectual property and market access challenges in overseas markets that are harming American innovators, patients, and workers.
Washington, D.C. (April 25, 2016) — Pharmaceutical Research and Manufacturers of America (PhRMA) senior vice president Robert Zirkelbach today released the following statement in response to the Campaign for Sustainable Rx Pricing’s proposals:
“These so-called market-based proposals are nothing more than a litany of new government regulations and mandates that would undermine the competitive market and empower government bureaucrats and insurance companies to make one-size-fits-all treatment decisions for patients.
Washington, D.C. (April 7, 2016) Pharmaceutical Research and Manufacturers of America (PhRMA) issued the following statement on recommendations voted on at MedPAC’s April meeting:
“PhRMA strongly opposes the sweeping new Medicare Part D recommendations approved by MedPAC earlier today. Taken together, these recommendations will significantly harm beneficiaries by eroding coverage and protections for some of the most vulnerable enrollees in the program. MedPAC’s vote also ignores broad stakeholder concerns raised in response to these proposals.
Washington, D.C. (March 17, 2016) -- Pharmaceutical Research and Manufacturers of America (PhRMA) issued the following statement on the FDA and NIH Workforce Authorities Modernization Act:
“To fulfill its central mission of protecting public health by fostering timely patient access to safe and effective new medicines, the U.S. Food and Drug Administration (FDA) needs the ability to hire and retain sufficient numbers and types of technical and scientific experts to efficiently conduct reviews of human drug applications.
“While we are still reviewing the language in the Senate bill, we support enhanced hiring authority at the FDA as well as the National Institutes of Health (NIH).
Washington, D.C. (March 10, 2016) — Today, at the Pharmaceutical Research and Manufacturers of America (PhRMA) Board Meeting, new officers were elected to the board of directors. George A. Scangos, CEO, Biogen, was elected chairman of the PhRMA board. Joaquin Duato, worldwide chairman, pharmaceuticals, Johnson & Johnson was elected chairman-elect and Joseph Jimenez, CEO, Novartis AG assumed the role of board treasurer.
Scangos formerly held the position of chairman-elect and succeeds Kenneth C. Frazier chairman and CEO of Merck & Co., Inc. as PhRMA board chairman.
Washington, D.C. (March 10, 2016) — Today, at the Pharmaceutical Research and Manufacturers of America (PhRMA) 2016 Annual Meeting, PhRMA president and CEO Stephen J. Ubl announced the association’s policy solutions for delivering innovative treatments to patients.
“I am a passionate believer in the power of biomedical innovation to save and improve lives,” Ubl said. “We are on the cusp of a golden era in medical discovery and have the potential to revolutionize the treatment of costly and debilitating diseases. But we can’t take this progress for granted.
“Now is the time for PhRMA to play a leadership role in advancing pragmatic, pro-consumer policies that enhance the private market and address costs holistically.”
Washington, D.C. (March 10, 2016) — Today, the Pharmaceutical Research and Manufacturers of America (PhRMA) honored 13 employees from 12 biopharmaceutical companies as “We Work For Health Champions” for their extraordinary efforts in policy advocacy and community service.
Established in 2009, the We Work for Health Champion Awards were created by the biopharmaceutical industry to honor employees who have not only excelled in their careers, but also shown an outstanding commitment to their communities through advocacy, community outreach, educational programs, community service and corporate education programs.
WASHINGTON, D.C. (March 8, 2016) – Today the Pharmaceutical Research and Manufacturers of America (PhRMA) spokesperson Allyson Funk provided the following statement in reaction to a newly released ASPE Issue Brief on Medicare Part B drugs and proposed Part B changes:
Washington, D.C. (March 8, 2016) — Pharmaceutical Research and Manufacturers of America (PhRMA) spokesperson Holly Campbell issued the following statement:
WASHINGTON (March 7, 2015) — America’s biopharmaceutical research companies are working to advance the treatment of osteoporosis with nine medicines in development, according to a new report released today by the Pharmaceutical Research and Manufacturers of America (PhRMA) and the National Osteoporosis Foundation (NOF).
Nearly 54 million Americans live with osteoporosis or low bone density, and that number is expected to reach more than 71 million by 2030. What’s more, half of women and a quarter of men over the age of 50 are expected to break a bone as a result of osteoporosis. New treatments and innovations in development by biopharmaceutical companies are providing hope for these Americans and their families.
WASHINGTON, D.C. (March 1, 2016) – Today the Pharmaceutical Research and Manufacturers of America (PhRMA) spokesperson Allyson Funk provided the following statement in reaction to a study published in BMJ on physician-administered drugs:
“Biopharmaceutical companies are committed to developing medicines that help patients live longer, healthier lives and, in recent decades, there have been tremendous advances in treatment options for patients including those with cancer, arthritis and hepatitis C.
BOSTON, MA – February 24, 2016 - Earlier today, representatives of local law enforcement and the Pharmaceutical Research and Manufacturers of America (PhRMA) were joined by Governor Charlie Baker at the Massachusetts State House to formally launch "MyOldMeds Massachusetts,” a public information campaign to drive awareness around safe prescription drug use, storage and disposal. The campaign also highlights existing resources for returning unused medicines to certain locations and provides information on substance abuse treatment options in the Commonwealth.
Washington D.C. (January 19, 2016) – The Pharmaceutical Research and Manufacturers of America (PhRMA) today announced that Rodger Currie will join the association as executive vice president for advocacy. He will lead federal, state and international government affairs and alliance development. Currie returns to PhRMA on February 1, 2016.
Washington, DC (January 7, 2016) The Pharmaceutical Research and Manufacturers of America (PhRMA) has appointed Amy Jackson as its new representative in Japan. As PhRMA’s Japan Representative, Ms. Jackson will coordinate the activities of PhRMA’s office in Tokyo and advocate for America’s research-based pharmaceutical companies on government, economic and health care policy matters in Japan.
Washington, D.C. (October 5, 2015) — Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO, John Castellani, issued the following statement:
“PhRMA believes that strong intellectual property protection is necessary for the discovery and development of new treatments and therapies for the world’s patients.
“We are disappointed that the Ministers failed to secure 12 years of data protection for biologic medicines, which represent the next wave of innovation in our industry. This term was not a random number, but the result of a long debate in Congress, which determined that this period of time captured the appropriate balance that stimulated research but gave access to biosimilars in a timely manner.